Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Just days after getting FDA approval for Fabhalta as the first oral therapy for paroxysmal nocturnal haemoglobinuria (PNH), Novartis has reported new data showing it is also effective in C3 ...

Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

NATALEE subanalysis evaluates Kisqali in pre-menopausal early breast cancer patients, amid rising diagnosis rates in younger patients Pluvicto analysis and Scemblix ASC4START primary endpoint results ...

Novartis’ efforts to strengthen its wide ... Kesimpta, Pluvicto, Scemblix, Kisqali, Leqvio and Fabhalta should fuel growth. NVS sits at a Zacks Rank #3 (Hold), holds a Momentum Style Score ...

Arrowhead Pharmaceuticals, Inc.'s deal with Sarepta expands its pipeline, but limited plozasiran market and competition ...

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

FILSPARI holds strong market potential as the first FDA-approved non-immunosuppressive therapy for IgA nephropathy, a rare kidney disease with significant unmet needs. As more patients and providers ...

There are already four approved therapies to treat IgAn — Novartis' Fabhalta — $129m revenues in 2024, Calliditas Therapeutics Tarpeyo — ~$150m revenues, and Travere Therapeutics (TVTX ...